Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Health

    Green signal for first stem cell therapy, novel HIV drug

    By WANG XIAOYU | chinadaily.com.cn | Updated: 2025-01-03 21:34
    Share
    Share - WeChat

    China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication associated with bone marrow transplant, as well as a novel HIV drug that only requires two shots yearly.

    The National Medical Products Administration said on Thursday that it granted conditional approval to an injection from the domestic drugmaker Platinum Life to treat patients aged 14 and above who suffer a rare disease called acute graft-versus-host disease and do not respond to regular steroid therapy.

    Acute graft-versus-host disease, or aGVHD, typically hits patients who have just undergone a stem cell transplant due to severe blood condition. The disease is one of the primary reasons of death following transplantation.

    The homegrown therapy is the first mesenchymal stromal cell treatment that has gained the greenlight on the Chinese mainland. The approval was issued through an accelerated market registration track designed for novel or urgently needed medicines.

    Stem cell therapy utilizes the differentiation and self-renewal capacity of stem cells to repair tissues and treat diseases. It represents a booming research field being studied worldwide to treat a variety of illnesses, including diabetes, Parkinson's disease and cancer.

    In China, the nation's first drug manufacturing license for stem cell treatment was issued in late May by the Beijing Municipal Medical Products Administration to Platinum Life.

    Chen Jiekai, a researcher at Chinese Academy of Sciences' Guangzhou Institutes of Biomedicine and Health, said that the issue of the license constitutes a key step toward clinical applications of stem cell treatment and signals the establishment of a complete supervision procedure for this kind of novel therapy.

    During an academic conference held in Guangzhou, Guangdong province in early December, he said that there are hundreds of clinical research projects on stem cell treatment across the nation, and a total of 141 hospitals have registered with a national medical research platform in preparation for carrying out stem cell clinical studies, local media reported.

    Also on Thursday, China approved lenacapavir, a long-acting HIV drug made by global biopharmaceutical company Gilead Sciences, according to the administration and the company.

    The treatment is approved to treat HIV patients who have multidrug resistance and cannot have their viral load effectively suppressed under available drug regimens.

    It was first approved in Europe and the United States in 2022, and research is underway to test its potential in preventing infection.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    无码精品人妻一区二区三区影院 | 日日麻批免费40分钟无码| 少妇人妻无码精品视频app| 忘忧草在线社区WWW中国中文| 亚洲AV无码片一区二区三区| 日韩精品一区二三区中文| 免费AV一区二区三区无码| 中文字幕一区二区三区日韩精品| 亚洲AⅤ无码一区二区三区在线| 欧美日韩中文字幕在线看| 亚洲人成影院在线无码观看| 亚洲av日韩av无码| 中文字幕无码不卡免费视频| 国产亚洲中文日本不卡二区| 亚洲国产AV无码专区亚洲AV| 成人精品一区二区三区中文字幕 | 无码人妻精品一区二区蜜桃百度 | 99无码人妻一区二区三区免费| 日韩精品一区二区三区中文字幕| 亚洲午夜无码片在线观看影院猛 | 人妻丰满熟妇无码区免费| 无码任你躁久久久久久老妇App| 国产精品无码日韩欧| 亚欧免费无码aⅴ在线观看| 制服中文字幕一区二区| 国产成人AV无码精品| 乱色精品无码一区二区国产盗| 日本无码WWW在线视频观看| 最近中文字幕高清字幕在线视频| 免费无码中文字幕A级毛片| 少妇无码太爽了不卡视频在线看| 久久久噜噜噜久久中文字幕色伊伊| 国产无码网页在线观看| 国产成人无码精品一区在线观看| 911国产免费无码专区| 国产精品午夜无码AV天美传媒 | 无码AV岛国片在线播放| 无码人妻精品中文字幕免费| 亚洲AV无码不卡无码| 色偷偷一区二区无码视频| 人妻无码视频一区二区三区|